[go: up one dir, main page]

WO2012006368A3 - Compositions and methods for treating influenza - Google Patents

Compositions and methods for treating influenza Download PDF

Info

Publication number
WO2012006368A3
WO2012006368A3 PCT/US2011/043095 US2011043095W WO2012006368A3 WO 2012006368 A3 WO2012006368 A3 WO 2012006368A3 US 2011043095 W US2011043095 W US 2011043095W WO 2012006368 A3 WO2012006368 A3 WO 2012006368A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
treating influenza
combination
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/043095
Other languages
French (fr)
Other versions
WO2012006368A2 (en
Inventor
David E. Anderson
Andrei Ogrel
Ronald Erwin Boch
Jeff Baxter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Variation Biotechnologies Inc
Original Assignee
Variation Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc
Publication of WO2012006368A2 publication Critical patent/WO2012006368A2/en
Publication of WO2012006368A3 publication Critical patent/WO2012006368A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compositions and methods useful for treating influenza that include an influenza virus hemagglutinin antigen in combination with lipid vesicles that include a non-ionic surfactant (NISVs) and/or in combination with a TLR-3 agonist adjuvant are descibed. The compositions remain potent even when they are not stored in a standard cold-chain system (i.e., they are thermostable).
PCT/US2011/043095 2010-07-06 2011-07-06 Compositions and methods for treating influenza Ceased WO2012006368A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36189910P 2010-07-06 2010-07-06
US61/361,899 2010-07-06
US201161431278P 2011-01-10 2011-01-10
US61/431,278 2011-01-10

Publications (2)

Publication Number Publication Date
WO2012006368A2 WO2012006368A2 (en) 2012-01-12
WO2012006368A3 true WO2012006368A3 (en) 2012-03-15

Family

ID=45441782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/043095 Ceased WO2012006368A2 (en) 2010-07-06 2011-07-06 Compositions and methods for treating influenza

Country Status (1)

Country Link
WO (1) WO2012006368A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CN103096922B (en) 2010-07-06 2019-08-06 变异生物技术公司 For treating the composition and method of influenza
EP2663327A4 (en) * 2011-01-13 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
CN104302323A (en) 2012-01-12 2015-01-21 变异生物技术公司 Compositions and methods for treating viral infections
CN104244984B (en) * 2012-01-27 2020-03-31 变异生物技术公司 Methods and compositions for therapeutic agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264273A1 (en) * 2003-06-18 2007-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingoid polyalklamine conjugates, isomers and uses thereof
US20100080844A1 (en) * 2002-07-05 2010-04-01 Andrew David Bacon Method to enhance an immune response of nucleic acid vaccination

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100080844A1 (en) * 2002-07-05 2010-04-01 Andrew David Bacon Method to enhance an immune response of nucleic acid vaccination
US20070264273A1 (en) * 2003-06-18 2007-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingoid polyalklamine conjugates, isomers and uses thereof

Also Published As

Publication number Publication date
WO2012006368A2 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
WO2012006367A3 (en) Compositions and methods for treating influenza
WO2012006368A3 (en) Compositions and methods for treating influenza
WO2009001217A3 (en) Low-additive influenza vaccines
HK1201186A1 (en) Solid compositions comprising an hcv inhibitor
WO2009031043A3 (en) Compositions comprising yersinia pestis antigens
WO2007098186A3 (en) Adjuvant and vaccine compositions
CL2014002509A1 (en) A composition comprising at least one source of boron and at least one source of silicon; product comprising substrate and composition; a method of providing a coated product; use of the composition.
WO2009085025A3 (en) System and method for sparql-query processing using parametrized-sparql-query in dbms-based systems
WO2013054199A3 (en) Cmv antigens and uses thereof
WO2010119343A3 (en) Compositions for immunising against staphylococcus aerus
MX2010008799A (en) Process for stabilizing an adjuvant containing vaccine composition.
WO2012100224A3 (en) Preparation of metal-triazolate frameworks
WO2008147496A3 (en) Neuraminidase-deficient live influenza vaccines
WO2012121547A3 (en) Adhesive composition for a wafer processing film
WO2012080833A3 (en) Controlled release dosage forms
WO2008054481A3 (en) Improved inactivated influenza virus compositions
HK1221641A1 (en) Vaccine composition and method of use
WO2013055877A3 (en) Key with fixed key pin protruding from a key -cut surface
CL2013001737A1 (en) Cleaning composition comprising a non-ionic surfactant, inorganic base nanoparticles and a secondary surfactant; ready-to-use cleaning formulation comprising said composition; and composition for cleaning hard surfaces.
WO2009120380A3 (en) Recombinant rhinovirus vectors
MX357477B (en) Choline salt cleaning compositions.
WO2013111012A3 (en) Methods and compositions for therapeutic agents
WO2014100465A3 (en) Temperature stable cloquintocet-mexyl aqueous compositions
MX359103B (en) Compositions and methods for treating viral infections.
WO2012138611A3 (en) Customizable interfacing agents, systems, and methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11804306

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11804306

Country of ref document: EP

Kind code of ref document: A2